Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGRM 
Monogram Orthopaedics Inc. Common Stock (MGRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/06/2025: MGRM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.22% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 243.79M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.69 | 52 Weeks Range 1.92 - 6.42 | Updated Date 10/14/2025 |
52 Weeks Range 1.92 - 6.42 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -72.9% | Return on Equity (TTM) -228.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 228415936 | Price to Sales(TTM) 243.53 |
Enterprise Value 228415936 | Price to Sales(TTM) 243.53 | ||
Enterprise Value to Revenue 230.43 | Enterprise Value to EBITDA -5.1 | Shares Outstanding 40632367 | Shares Floating 30581545 |
Shares Outstanding 40632367 | Shares Floating 30581545 | ||
Percent Insiders 54.55 | Percent Institutions 4.97 |
Upturn AI SWOT
Monogram Orthopaedics Inc. Common Stock
Company Overview
History and Background
Monogram Orthopaedics Inc. was founded to develop and commercialize patient-specific solutions in orthopedics, focusing on robotic surgical technology and personalized implants. The company aims to improve surgical outcomes and patient satisfaction.
Core Business Areas
- Robotics-assisted Surgical Solutions: Develops a robotic surgical system for total joint replacement surgeries, particularly focusing on the knee.
- Personalized Implants: Designs and manufactures patient-specific orthopedic implants tailored to individual anatomy using advanced imaging and 3D printing technologies.
Leadership and Structure
The leadership team consists of experienced professionals in orthopedics, robotics, and medical device development. The organizational structure is designed to foster innovation and efficient execution of its strategic goals. Benjamin Sexson serves as the Chief Executive Officer.
Top Products and Market Share
Key Offerings
- mBESS Robotic System: This system aims to automate key steps in knee replacement surgery, enhancing precision and repeatability. While specific market share data is not publicly available, competitors in the robotic surgery space include Stryker's Mako system and Zimmer Biomet's ROSA Knee System. Revenue figures are not publicly available as the system is pre-commercial.
- Patient-Specific Implants: Implants are designed using 3D printing. Market share information is not publicly available. Competitors include Conformis and other custom implant manufacturers. Revenue figures are not publicly available as the system is pre-commercial.
Market Dynamics
Industry Overview
The orthopedic market is driven by an aging population, increasing rates of osteoarthritis, and technological advancements in surgical procedures and implant designs. The industry is highly competitive and regulated.
Positioning
Monogram Orthopaedics is positioning itself as a disruptor in the orthopedic market by providing personalized surgical solutions, improved surgical outcomes. It offers a distinct advantage within the patient-specific approach
Total Addressable Market (TAM)
The total addressable market for orthopedic implants and robotic surgery is estimated to be in the tens of billions of dollars. Monogram Orthopaedics is targeting a niche within this market with its personalized approach, aiming to capture a significant share as the technology matures and gains wider acceptance.
Upturn SWOT Analysis
Strengths
- Proprietary robotic surgical technology
- Personalized implant design capabilities
- Potential for improved surgical outcomes
- Strong intellectual property portfolio
Weaknesses
- Pre-commercial stage with no current revenue
- Limited market presence and brand recognition
- Dependence on regulatory approvals
- High capital expenditure for product development and manufacturing
Opportunities
- Expanding applications to other orthopedic procedures
- Strategic partnerships with hospitals and surgeons
- Increasing adoption of robotic surgery
- Growing demand for personalized implants
Threats
- Competition from established orthopedic companies
- Regulatory hurdles and delays
- Technological obsolescence
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- STRY (Stryker Corporation)
- ZBH (Zimmer Biomet Holdings, Inc.)
- CONM (Conmed Corporation)
Competitive Landscape
Monogram Orthopaedics faces significant competition from established players with greater resources and broader product portfolios. Its advantages lie in its personalized approach and proprietary robotic technology. Success depends on demonstrating improved outcomes and cost-effectiveness compared to existing solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the development of its robotic system and personalized implant technology. The company is focused on securing regulatory approvals and commercializing its products.
Future Projections: Future growth is contingent on successful regulatory approvals, commercialization efforts, and market adoption of its robotic system and personalized implants. Analyst estimates vary widely due to the speculative nature of the stock. The company has forecasted revenue once commercialized, but these are speculative and subject to change.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, product development enhancements, and strategic partnerships.
Summary
Monogram Orthopaedics is a pre-commercial stage company that specializes in personalized orthopedics. Its strength lies in its proprietary robotic technology and personalized implant design. Key challenges include securing regulatory approvals and competing with established industry giants. The company's success hinges on successful commercialization and market adoption of its innovative solutions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and represents a general overview. It is not financial advice, and readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Market data and estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monogram Orthopaedics Inc. Common Stock
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2023-05-18 | Chairman of the Board, President & CEO Mr. Benjamin Sexson C.F.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 27 | |
Full time employees 27 | |||
As of October 7, 2025, Monogram Technologies Inc. was acquired by Zimmer Biomet Holdings, Inc.. Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.